Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer

The signifier 3 TAISHAN-302 proceedings recovered that tambotatug pelitecan (Tam-Peli, YL201), a caller anti-B7-H3 antibody-drug conjugate, importantly improved wide survival, progression-free endurance and nonsubjective effect complaint compared with topotecan successful patients with relapsed small-cell lung crab (SCLC). The findings were presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).